About the project This project stems from the Evidence, Policy and Influence Collaborative, led by Prof Lisa Bero, which seeks to translate rigorous and unbiased evidence into clinical practice and health policy. One facet of this Collaborative is the study of bias in healthcare: we sought to understand the extent of pharmaceutical industry marketing in the form of payments to health professionals as a means to begin tracing the influence of marketing on clinical care. About the dataset This dataset contains details of the payments received by Health Professionals in Australia from the pharmaceutical industry from May 2016 to April 2017. Data were accessed on 2 and 27 September 2017 from openly available individual member company reports t...
Background: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
BACKGROUND: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
Aims: One tool for protecting quality use of medicines in hospitals is a drug and therapeutics commi...
This project stems from the Evidence, Policy and Influence Collaborative, led by Prof Lisa Bero, whi...
The dataset contains pharmaceutical company reports of payments to Australian healthcare professiona...
The dataset contains reports of pharmaceutical company sponsorship of educational events for healthc...
Objectives To analyse patterns and characteristics of pharmaceutical industry sponsorship of events ...
This dataset contains all payments from external donors received by health related All-Party Parliam...
OBJECTIVES: To describe and quantify disclosed payments from the pharmaceutical industry to the heal...
Objectives: To analyse the section of Disclosure UK that pertains to healthcare professionals (HCPs)...
BackgroundMany patient organisations collaborate with drug companies, resulting in concerns about co...
Objective: A wealth of data is generated through Australia's universal health care arrangements. How...
Background: The pharmaceutical industry makes large numbers of payments to healthcare organisations ...
BackgroundMany patient organisations collaborate with drug companies, resulting in concerns about co...
Pharmaceutical scandals frequently occupy national media headlines, and these controversial practice...
Background: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
BACKGROUND: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
Aims: One tool for protecting quality use of medicines in hospitals is a drug and therapeutics commi...
This project stems from the Evidence, Policy and Influence Collaborative, led by Prof Lisa Bero, whi...
The dataset contains pharmaceutical company reports of payments to Australian healthcare professiona...
The dataset contains reports of pharmaceutical company sponsorship of educational events for healthc...
Objectives To analyse patterns and characteristics of pharmaceutical industry sponsorship of events ...
This dataset contains all payments from external donors received by health related All-Party Parliam...
OBJECTIVES: To describe and quantify disclosed payments from the pharmaceutical industry to the heal...
Objectives: To analyse the section of Disclosure UK that pertains to healthcare professionals (HCPs)...
BackgroundMany patient organisations collaborate with drug companies, resulting in concerns about co...
Objective: A wealth of data is generated through Australia's universal health care arrangements. How...
Background: The pharmaceutical industry makes large numbers of payments to healthcare organisations ...
BackgroundMany patient organisations collaborate with drug companies, resulting in concerns about co...
Pharmaceutical scandals frequently occupy national media headlines, and these controversial practice...
Background: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
BACKGROUND: The Pharmaceutical Benefits Scheme (PBS) is Australia's national drug subsidy program. T...
Aims: One tool for protecting quality use of medicines in hospitals is a drug and therapeutics commi...